Published in JAMA on September 01, 2010
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet (2012) 4.45
BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. J Clin Oncol (2012) 3.86
Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res (2012) 3.33
Clinical evaluation of a multiple-gene sequencing panel for hereditary cancer risk assessment. J Clin Oncol (2014) 3.12
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04
Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol (2014) 2.85
Perceptions, knowledge, and satisfaction with contralateral prophylactic mastectomy among young women with breast cancer: a cross-sectional survey. Ann Intern Med (2013) 2.76
Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ (2014) 2.60
Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. J Clin Oncol (2014) 2.19
Population-based screening for breast and ovarian cancer risk due to BRCA1 and BRCA2. Proc Natl Acad Sci U S A (2014) 1.95
Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer. J Clin Oncol (2014) 1.91
Genetics, genomics, and cancer risk assessment: State of the Art and Future Directions in the Era of Personalized Medicine. CA Cancer J Clin (2011) 1.90
Personalized medicine: new genomics, old lessons. Hum Genet (2011) 1.85
Exome sequencing identifies rare deleterious mutations in DNA repair genes FANCC and BLM as potential breast cancer susceptibility alleles. PLoS Genet (2012) 1.84
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
RANK ligand as a potential target for breast cancer prevention in BRCA1-mutation carriers. Nat Med (2016) 1.55
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet (2011) 1.51
Identification and Management of Women With BRCA Mutations or Hereditary Predisposition for Breast and Ovarian Cancer. Mayo Clin Proc (2010) 1.51
Risk-reducing salpingo-oophorectomy and ovarian cancer screening in 1077 women after BRCA testing. JAMA Intern Med (2013) 1.43
Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancer (2011) 1.41
Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. J Clin Oncol (2017) 1.40
Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol (2012) 1.35
Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2013) 1.29
Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network. J Clin Oncol (2012) 1.28
Building the foundation for genomics in precision medicine. Nature (2015) 1.28
Dealing with the unexpected: consumer responses to direct-access BRCA mutation testing. PeerJ (2013) 1.26
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. JAMA (2015) 1.26
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany. J Community Genet (2011) 1.23
The risk of contralateral breast cancer in patients from BRCA1/2 negative high risk families as compared to patients from BRCA1 or BRCA2 positive families: a retrospective cohort study. Breast Cancer Res (2012) 1.22
Quantitative assessment of background parenchymal enhancement in breast MRI predicts response to risk-reducing salpingo-oophorectomy: preliminary evaluation in a cohort of BRCA1/2 mutation carriers. Breast Cancer Res (2015) 1.20
GWAS identifies a common breast cancer risk allele among BRCA1 carriers. Nat Genet (2010) 1.19
Hereditary breast and ovarian cancer: new genes, new treatments, new concepts. Dtsch Arztebl Int (2011) 1.17
A national initiative for women and healthcare providers: CDC's Inside Knowledge: Get the Facts About Gynecologic Cancer campaign. J Womens Health (Larchmt) (2011) 1.15
A computational method to classify variants of uncertain significance using functional assay data with application to BRCA1. Cancer Epidemiol Biomarkers Prev (2011) 1.15
Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer (2012) 1.14
Population sciences, translational research, and the opportunities and challenges for genomics to reduce the burden of cancer in the 21st century. Cancer Epidemiol Biomarkers Prev (2011) 1.13
Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis. J Natl Cancer Inst (2014) 1.11
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
Long-term psychosocial outcomes of BRCA1/BRCA2 testing: differences across affected status and risk-reducing surgery choice. Cancer Epidemiol Biomarkers Prev (2012) 1.08
BRCA mutation testing in determining breast cancer therapy. Cancer J (2011) 1.07
Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Res Treat (2011) 1.06
Prevalence and healthcare actions of women in a large health system with a family history meeting the 2005 USPSTF recommendation for BRCA genetic counseling referral. Cancer Epidemiol Biomarkers Prev (2013) 1.05
Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Cancer (2013) 1.04
Risk-reducing salpingo-oophorectomy: a meta-analysis on impact on ovarian cancer risk and all cause mortality in BRCA 1 and BRCA 2 mutation carriers. BMC Womens Health (2014) 1.02
Cancer treatment according to BRCA1 and BRCA2 mutations. Nat Rev Clin Oncol (2012) 1.01
BRCA1/2 mutations and triple negative breast cancers. Breast Dis (2010) 0.99
Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer (2013) 0.98
Challenges in the gynecologic care of premenopausal women with breast cancer. Mayo Clin Proc (2011) 0.98
Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research. Genet Med (2013) 0.98
Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer (2014) 0.97
Contralateral risk-reducing mastectomy: review of risk factors and risk-reducing strategies. Int J Surg Oncol (2015) 0.96
[Guideline for the prevention and early detection of breast and ovarian cancer in high risk patients, particularly in women from HBOC (hereditary breast and ovarian cancer) families]. Wien Klin Wochenschr (2012) 0.95
Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med (2016) 0.95
Exercise lowers estrogen and progesterone levels in premenopausal women at high risk of breast cancer. J Appl Physiol (1985) (2011) 0.95
Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol (2015) 0.95
Acceptability of prophylactic salpingectomy with delayed oophorectomy as risk-reducing surgery among BRCA mutation carriers. Gynecol Oncol (2014) 0.94
Impact of genetic testing on endometrial cancer risk-reducing practices in women at risk for Lynch syndrome. Gynecol Oncol (2012) 0.94
Pharmacogenetic testing affects choice of therapy among women considering tamoxifen treatment. Genome Med (2011) 0.94
Common breast cancer risk variants in the post-COGS era: a comprehensive review. Breast Cancer Res (2013) 0.94
Effects of age on the detection and management of breast cancer. Cancers (Basel) (2015) 0.94
Genetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting. Cancer Control (2012) 0.93
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med (2014) 0.93
Multiplex genetic testing: reconsidering utility and informed consent in the era of next-generation sequencing. Genet Med (2014) 0.93
Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine (2015) 0.93
Collaborative cancer epidemiology in the 21st century: the model of cancer consortia. Cancer Epidemiol Biomarkers Prev (2013) 0.92
Hereditary breast cancer: clinical, pathological and molecular characteristics. Breast Cancer (Auckl) (2014) 0.92
Breast and ovarian cancer risk and risk reduction in Jewish BRCA1/2 mutation carriers. J Clin Oncol (2012) 0.91
Bilateral oophorectomy, body mass index, and mortality in U.S. women aged 40 years and older. Cancer Prev Res (Phila) (2012) 0.91
The korean hereditary breast cancer study: review and future perspectives. J Breast Cancer (2013) 0.90
Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genet Med (2014) 0.90
Identification of a comprehensive spectrum of genetic factors for hereditary breast cancer in a Chinese population by next-generation sequencing. PLoS One (2015) 0.89
A preliminary investigation of genetic counselors' information needs when receiving a variant of uncertain significance result: a mixed methods study. Genet Med (2015) 0.89
Challenging and complex decisions in the management of the BRCA mutation carrier. J Womens Health (Larchmt) (2013) 0.89
Looking different, feeling different: women's reactions to risk-reducing breast and ovarian surgery. Fam Cancer (2012) 0.88
The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers. Front Biosci (Landmark Ed) (2014) 0.88
Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay. Hum Mol Genet (2012) 0.88
Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol (2016) 0.87
Proposed roadmap to stepwise integration of genetics in family medicine and clinical research. Clin Transl Med (2013) 0.87
Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review. Int J Surg Oncol (2011) 0.86
Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients. Ann Surg Oncol (2012) 0.86
Drug therapy for hereditary cancers. Hered Cancer Clin Pract (2011) 0.85
Effect of tubal sterilization technique on risk of serous epithelial ovarian and primary peritoneal carcinoma. Gynecol Oncol (2014) 0.85
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol (2016) 0.85
New hypothesis on pathogenesis of ovarian cancer lead to future tailored approaches. Biomed Res Int (2013) 0.84
Oophorectomy: the debate between ovarian conservation and elective oophorectomy. Menopause (2013) 0.84
Lessons learned from genetic testing. JAMA (2010) 0.84
Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer. Fam Cancer (2017) 0.84
Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract (2015) 0.84
Efficient identification and referral of low-income women at high risk for hereditary breast cancer: a practice-based approach. Public Health Genomics (2012) 0.83
Genetic testing for hereditary cancer predisposition: BRCA1/2, Lynch syndrome, and beyond. Gynecol Oncol (2016) 0.83
Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru. Clin Genet (2014) 0.83
To worry or not to worry: breast cancer genetic counseling communication with low-income Latina immigrants. J Community Genet (2014) 0.82
Effectiveness of oncogenetics training on general practitioners' consultation skills: a randomized controlled trial. Genet Med (2013) 0.82
Development and evaluation of a decision aid for BRCA carriers with breast cancer. J Genet Couns (2011) 0.82
Do Breast Cancer Patients Tested in the Oncology Care Setting Share BRCA Mutation Results with Family Members and Health Care Providers? J Cancer Epidemiol (2012) 0.81
Changes of Socio-demographic data of clients seeking genetic counseling for hereditary breast and ovarian cancer due to the "Angelina Jolie Effect". BMC Cancer (2016) 0.81
Participation of low-income women in genetic cancer risk assessment and BRCA 1/2 testing: the experience of a safety-net institution. J Community Genet (2015) 0.81
Use of risk-reducing surgeries in a prospective cohort of 1,499 BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat (2014) 0.81
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med (1997) 13.96
Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science (2003) 13.19
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2002) 7.84
Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol (2007) 7.46
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. Br J Cancer (2000) 4.37
Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. Neurology (2007) 4.28
Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med (2001) 4.13
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol (2004) 3.86
Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. Lancet Oncol (2006) 3.81
Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol (2005) 3.63
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol (2005) 3.44
Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst (1999) 3.26
Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol (2006) 3.02
Effect of short-term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2005) 2.70
Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol (2006) 2.49
Increased risk of parkinsonism in women who underwent oophorectomy before menopause. Neurology (2007) 2.22
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. Clin Cancer Res (2002) 2.16
Prophylactic oophorectomy reduces breast cancer penetrance during prospective, long-term follow-up of BRCA1 mutation carriers. J Clin Oncol (2005) 2.11
Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. J Natl Cancer Inst (2003) 2.04
Potential for bias in studies on efficacy of prophylactic surgery for BRCA1 and BRCA2 mutation. J Natl Cancer Inst (2003) 2.02
Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol (2007) 1.54
Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev (2007) 1.36
Effect of bilateral oophorectomy on women's long-term health. Womens Health (Lond Engl) (2009) 1.21
Risk reducing mastectomy: outcomes in 10 European centres. J Med Genet (2008) 1.12
Prophylactic mastectomy for BRCA1/2 carriers: progress and more questions. J Clin Oncol (2004) 1.10
Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Res Treat (2009) 1.10
Oophorectomy and cardiovascular mortality: is there a link? Menopause (2009) 1.00
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA (2008) 13.35
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics (2006) 12.45
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Mutational processes molding the genomes of 21 breast cancers. Cell (2012) 11.22
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet (2010) 9.72
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res (2013) 9.31
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet (2010) 8.41
Colorectal cancer. Lancet (2010) 8.36
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med (2002) 8.09
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet (2008) 7.65
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
American Society of Clinical Oncology identifies five key opportunities to improve care and reduce costs: the top five list for oncology. J Clin Oncol (2012) 7.16
Multiple common variants for celiac disease influencing immune gene expression. Nat Genet (2010) 6.90
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol (2006) 6.86
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev (2004) 6.24
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) (2010) 5.81
Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med (2006) 5.70
Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol (2010) 5.50
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. N Engl J Med (2015) 5.39
Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol (2004) 5.38
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer. N Engl J Med (2010) 5.17
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Assessment of cumulative evidence on genetic associations: interim guidelines. Int J Epidemiol (2007) 4.96
Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol (2009) 4.84
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet (2011) 4.73
Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet (2004) 4.61
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735. J Clin Oncol (2009) 4.56
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res (2004) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet (2012) 4.45
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol (2006) 4.19
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA (2006) 4.09
Genetic predisposition directs breast cancer phenotype by dictating progenitor cell fate. Cell Stem Cell (2011) 4.08
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol (2006) 3.96